多柔比星联合洛铂术后化疗在宫颈癌根治术患者中的应用效果及对复发情况的影响  

Effect of Doxorubicin combined with Lobaplatin on postoperative chemotherapy in patients with radical cervical cancer and its effect on recurrence

作　　者：许娟秀[1] 谢燕 刘东琴 叶璐[1] 荆晓玲 吴海根[1] XU Juanxiu;XIE Yan;LIU Dongqin;YE Lu;JING Xiaoling;WU Haigen(Department of Oncology,Jiangxi Maternal and Child Health Hospital,Jiangxi Province,Nanchang 330006,China)

机构地区：[1]江西省妇幼保健院肿瘤科,江西南昌330006

出　　处：《中国当代医药》2025年第3期81-84,共4页China Modern Medicine

基　　金：江西省卫生健康委科技计划项目(202310942)。

摘　　要：目的探讨多柔比星联合洛铂术后化疗对宫颈癌根治术患者的疗效以及复发的影响。方法选取2020年1月至2023年3月江西省妇幼保健院收治的60例宫颈癌患者作为研究对象,根据随机数字表法分为观察组(30例)和对照组(30例)。观察组采用多柔比星联合洛铂治疗,对照组采用洛铂。比较两组的6个月生存率、局部复发率、远处转移情况,以及成纤维细胞生长因子受体4(FGFR4)、鳞状细胞癌抗原(SCCA)、脊椎蛋白2水平。结果化疗前,两组FGFR4和SCCA、脊椎蛋白2水平比较,差异无统计学意义(P>0.05);化疗后,观察组FGFR4、SCCA、脊椎蛋白2水平低于对照组,差异有统计学意义(P<0.05)。观察组并发症总发生率低于对照组,差异有统计学意义(P<0.05)。观察组生存率高于对照组,差异有统计学意义(P<0.05);观察组局部复发率及远处转移率低于对照组,差异有统计学意义(P<0.05)。结论接受宫颈癌根治术的患者,在术后化疗中使用多柔比星联合洛铂,可提升生存率,对避免疾病复发与转移可起到显著效果。Objective To investigate the effect of Doxorubicin combined with Lobaplatin on postoperative chemotherapy in patients with radical cervical cancer and its effect on recurrence.Methods A total of 60 patients with cervical cancer admitted to Jiangxi Maternal and Child Health Hospital from January 2020 to March 2023 were selected as the research objects.According to the random number table method,they were divided into observation group(30 cases)and control group(30 cases).The observation group was treated with Doxorubicin combined with Lobaplatin,and the control group was treated with Lobaplatin.Six-month survival,local recurrence rate,distant metastasis,and levels of fibroblast growth factor receptor 4(FGFR4),squamous cell carcinoma antigen(SCCA),and spondin-2 were compared between the two groups.Results Before chemotherapy,there were no significant differences in FGFR4,SCCA and spondin-2 levels between the two groups(P>0.05).After chemotherapy,the levels of FGFR4,SCCA and spondin-2 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of complications in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).The survival rate of observation group was higher than that of control group,and the difference was statistically significant(P<0.05).The local recurrence rate and distant metastasis rate of the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05).Conclusion In patients undergoing radical cervical cancer surgery,Doxorubicin combined with Lobaplatin in postoperative chemotherapy can improve the survival rate,and can play a significant role in avoiding recurrence and metastasis of the disease.

关 键 词：多柔比星 洛铂 宫颈癌根治术 生存率 并发症发生率 

分 类 号：R711.74[医药卫生—妇产科学]